

BioLight Invests in RevitalVision, a Developer of Vision-Improvement Software

BioLight, a company specializing in ophthalmic technologies, is expanding its digital therapeutics portfolio with an investment in a company that develops and markets home-use vision-improvement software in the US, Israel, and worldwide.

December 31, 2025

BioLight Life Sciences Ltd. (TASE: BOLT) announced today that it has completed an investment through which it may become a substantial shareholder in **RevitalVision**.

RevitalVision has developed a digital vision-improvement software, sold to both clinics and private consumers. The platform enables the improvement of visual capabilities through structured home-based training, requiring no specialized equipment. RevitalVision's product is FDA-cleared and regulatory-approved in Europe and Israel for the treatment of amblyopia (lazy eye) in adults and children over the age of 9. Additionally, the company sells online products for improving near and distance vision, as well as sports vision.

This move marks a strategic step in strengthening BioLight's portfolio and its presence in the ophthalmology sector. It offers potential synergy with another BioLight digital health portfolio company, **Peripherex Inc.**, which recently began US sales of its diagnostic product following FDA approval. BioLight maintains a robust portfolio of ophthalmic companies, advancing technologies from early stages to commercialization.

RevitalVision's training software is the only product in the world with FDA clearance for treating amblyopia in patients aged 9 and older - with no upper age limit - at a stage where standard patching treatments are no longer effective. A series of clinical studies published in 2025 demonstrated the software's efficacy in improving vision across various conditions and eye diseases, such as Keratoconus and Nystagmus. RevitalVision's solution is already in use in Israel and is covered by some of the country's leading health maintenance organizations (HMOs).

Yaacov Michlin, CEO of BioLight, stated: "RevitalVision's technology is a proven solution, extensively reviewed in professional literature and already utilized by thousands of patients. This investment reflects our strategy to invest in product-oriented companies at or near the sales stage, creating value for the company and its shareholders in the short to medium term. The extensive experience of BioLight and its team, combined with the RevitalVision team, will facilitate efforts to make these products widely accessible in the US, Israel, and globally."

Yair Yahav, CEO of RevitalVision, added: "We are pleased and proud of this partnership with BioLight, which marks a natural milestone in our company's evolution. It provides us with the tailwind needed to continue expanding, strengthening our presence in existing markets and exploring new opportunities, all while realizing our vision - to provide effective vision-improvement solutions to audiences worldwide."

About BioLight Life Sciences Ltd.

BioLight Life Sciences is a life sciences investment company focused on ophthalmology and advanced medical technologies. The company invests in and supports companies specializing in medical devices, pharmaceuticals, and digital health, from early-stage development to commercialization. Its operations combine capital investment with active involvement in strategy, regulation, business development, and market penetration, aiming to promote innovative solutions with broad application potential in global healthcare systems. BioLight is traded on the Tel Aviv Stock Exchange under the ticker **BOLT**.
